stockrowArmata Pharmaceuticals, Inc.
ARMP Healthcare Biotechnology
Armata Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 5.22% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +548.9%
- Free cash flow
- −18.0%
- Total debt
- +152.4%
Quarter to June 2026, against a year earlier
Follow ARMP
Alert me
Armata Pharmaceuticals, Inc. (ARMP) EV/Sales
As of 6 November 2026, Armata Pharmaceuticals, Inc. (ARMP) trades at a EV/Sales of 69.2×. Over the past ten years it has ranged from −47.0× (August 2017) to 611× (October 2018); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 124× | 445.67% |
| FY2024 | 22.7× | (47.07%) |
| FY2023 | 42.8× | 229.23% |
| FY2022 | 13.0× | (63.56%) |
| FY2021 | 35.7× | (42.56%) |
| FY2020 | 62.2× | 443.43% |
| FY2017 | 11.4× | — |
| FY2016 | −3.6× | — |
| FY2015 | 25.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 89.8× | (44.61%) |
| Mar 2026 | 162× | 30.99% |
| Dec 2025 | 124× | 161.13% |
| Sep 2025 | 47.4× | 40.17% |
| 32 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FHTX Foghorn Therapeutics Inc. compare | −0.4× |
| NKTX Nkarta, Inc. compare | n/m |
| PYPD PolyPid Ltd. compare | n/m |
| NERV Minerva Neurosciences, Inc compare | n/m |
| ENGN enGene Therapeutics Inc compare | n/m |
| CDXS Codexis, Inc. compare | 1.0× |
| CHRS Coherus Oncology, Inc. compare | 4.4× |
| HUMA Humacyte, Inc. compare | 41.4× |
| ARMP Armata Pharmaceuticals, Inc. | 69.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)